Fennec Pharmaceuticals (FENC) Cash from Financing Activities (2010 - 2025)

Fennec Pharmaceuticals (FENC) has 14 years of Cash from Financing Activities data on file, last reported at $20.8 million in Q4 2025.

• Quarterly Cash from Financing Activities rose 270.35% year-over-year to $20.8 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $22.6 million (up 266.19% YoY) and the FY2025 annual result came in at $22.6 million, up 266.19% from the prior year.
• Cash from Financing Activities grew to $20.8 million in Q4 2025, from $1.7 million in the prior quarter.
• In the past five years, Cash from Financing Activities ranged from a high of $20.8 million in Q4 2025 to a low of -$12.2 million in Q4 2024.
• A 5-year average of $2.1 million and a median of $201000.0 in 2023 frame the typical range for Cash from Financing Activities.
• Annual changes were most pronounced in 2022 — Cash from Financing Activities jumped 8140.0% — and 2024, when it tumbled 686.53%.
• Tracing FENC's Cash from Financing Activities over 5 years: stood at $10000.0 in 2021, then jumped by 8140.0% to $824000.0 in 2022, then jumped by 595.39% to $5.7 million in 2023, then slumped by 313.12% to -$12.2 million in 2024, then soared by 270.35% to $20.8 million in 2025.
• The last three Cash from Financing Activities figures came in at $20.8 million (Q4 2025), $1.7 million (Q3 2025), and -$284000.0 (Q2 2025), per Business Quant data.